Hyderabad-based Bharat Biotech had completed Phase-2 and Phase-3 trials of Covaxin on children below 18 years of age in September and submitted the trial data to the Drugs and Comptroller General of India (DCGI).

The made-in-India vaccine will be administered in two doses, with a gap of 20 days between the first and second dose.